AroCell’s Chief Scientific Officer, Professor Staffan Eriksson, presents today new preliminary results from the U-CAN TK1 lymphoma study at the International Society of Oncology Biomarkers (ISOBM) in Hamburg. The preliminary results suggest that TK 210 ELISA may be used for monitoring the effect of therapy of DLBCL patients under rituximab + CHOP treatment, and for determination of overall survival rate.
In the study TK 210 ELISA has been used for monitoring the effect of drug therapy (rituximab + CHOP) on patients suffering from DLBCL (Diffuse Large B-Cell Lymphoma), an aggressive form of non-Hodgkin’s lymphoma with an incidence of approximately 7 per 100 000 globally (United States National Cancer Institute’s SEER Database).
At the same congress, AroCell is presenting results from an additional study which show the analytical performance of TK 210 ELISA compared to activity-based methods, e.i. LIAISON® Thymidine Kinase, and 3H-dThd phosphorylation. The study is based on measuring TK1 concentration in serum samples from healthy blood donors and subjects with hematological malignancies, such as lymphoma, leukemia and multiple myeloma.
The results show that TK 210 ELISA has similar performance compared to LIAISON Thymidine Kinase and the 3H-dThd phosphorylation assay. The study also shows that AroCell’s unique Sample Dilution Buffer contributes to improve the diagnostic performance.
“The results from these studies suggest that TK 210 ELISA could be a valuable tool in the management of hematological malignancies such as DLBCL, as well as in breast cancer as previously described in Tumor Biology, 2016. While TK 210 ELISA correlates with other activity-based methods for measuring cell proliferation and disruption, it is also easy-to-use, reproducible, robust, and can be adapted to automated high-throughput ELISA platforms commonly used in clinical laboratories”, says Professor Eriksson.
Professor Eriksson’s presentation is available on:
For more information:
Johan von Heijne, Acting CEO
Telephone: +46(0)705-95 15 10
AroCell is obliged to make pubic this information pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of Johan von Heijne, November 27, 2018 at 15:00.
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser.